Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Inovio Biomedical Corporation said that its partner Tripep has treated the first subject in a Phase I/II clinical trial of a novel DNA vaccine, ChronVac-C, designed to treat chronically infected hepatitis C virus patients.
Subscribe to our email newsletter
In this trial, ChronVac-C will be administered using Inovio’s MedPulser DNA delivery system, in 12 subjects already infected with hepatitis C virus. The trial is being conducted in Sweden at two Karolinska University Hospitals, the Center for Gastroenterology in Solana and at the Infections Clinic in Huddinge.
Avtar Dhillon, Inovio’s president and CEO, said: “The treatment of the first subject in this clinical study of a novel therapeutic vaccine for a significant chronic pathogen is another step in a paradigm shift toward DNA-based vaccines that may address a number of diseases that have not been controllable using conventional prophylactic vaccination. We look forward to the development of a number of important therapeutic vaccines using Inovio’s proprietary delivery technology.”